| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/11/2004 | WO2004019868A2 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 03/11/2004 | WO2004009578A3 Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them |
| 03/11/2004 | WO2004000789A9 Amide linker peroxisome proliferator activated receptor modulators |
| 03/11/2004 | WO2003099759A8 Preparation and application of transhintotalphenolic acid |
| 03/11/2004 | WO2003097033A3 Novel neutracetical and pharmaceutical compositions and their uses |
| 03/11/2004 | WO2003092599A3 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 03/11/2004 | WO2003071268A3 Method for discovering pharmacologically active substances |
| 03/11/2004 | WO2003069346A3 Diagnostic method for stroke |
| 03/11/2004 | WO2003066003A3 Anti-pathogen treatements |
| 03/11/2004 | WO2003062247A3 Phosphinic pseudo-peptide derivatives for selective inhibition of the active c-terminal site of angiotensin converting enzyme (i) (ace) |
| 03/11/2004 | WO2003059323A3 Stable salts of o-acetylsalicylic acid containing basic amino acids ii |
| 03/11/2004 | WO2003057867A3 Regulation of human fatty acid coa ligase-like amp-binding enzyme |
| 03/11/2004 | WO2003056010A3 An antisense strategy to modulate estrogen receptor response (er. alpha. and/or er. beta.) |
| 03/11/2004 | WO2003051395A3 Edg-receptor agonist for the treatment of hypertension |
| 03/11/2004 | WO2003041736A3 Method for the treatment of cardiotoxicity induced by antitumor compounds |
| 03/11/2004 | WO2003037301A3 Oral dosage forms for improving the bioavailability of therapeutic agents |
| 03/11/2004 | WO2003033535A3 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| 03/11/2004 | WO2003015690B1 Method for treating primary insomnia |
| 03/11/2004 | WO2003009845A9 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/11/2004 | WO2003008548A3 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 03/11/2004 | WO2003002524A3 Urea derivatives with antiproteolytic activity |
| 03/11/2004 | WO2003000695A8 Pyrrolopyrimidines as protein kinase inhibitors |
| 03/11/2004 | WO2003000185A3 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 03/11/2004 | WO2002083709A3 Kinases and phosphatases |
| 03/11/2004 | WO2002079441A3 Secreted proteins |
| 03/11/2004 | WO2002076404A3 Fatty alcohol drug conjugates |
| 03/11/2004 | US20040049083 Arylpiperazines having activity at the serotonin 1A receptor |
| 03/11/2004 | US20040049036 From diphenyl (4-(4-fluorophenyl)-6-isopropyl-2-(methyl-(methyl sulfonyl)amino)pyrimidin-5-ylmethyl)phosphine and tert-butyl-2-((4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl) acetate; removal of tert-butyl group to form acid or salt |
| 03/11/2004 | US20040049032 Inhibitors of protein kinases, especially Aurora kinase; anticancer agents |
| 03/11/2004 | US20040049023 Useful in the study of vascular smooth muscle cell proliferation and in the treatment of blood vessel diseases that result from excessive smooth muscle cell proliferation, particularly after balloon angioplasty |
| 03/11/2004 | US20040049017 A protein complex which includes a growth factor, growth factor binding protein and vitronectin; for treating cancers, psoriasis, atherosclerosis and wounds prone to hypertrophic scarring |
| 03/11/2004 | US20040048931 Modafinil pharmaceutical compositions |
| 03/11/2004 | US20040048929 E.g., N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal stabilized with a lipid; improved absorption and penetration; treating ischemia, immune diseases, Alzheimer's disease, osteoporosis, brain disorders, eye diseases, osteoporosis |
| 03/11/2004 | US20040048920 2-(p-(1-hydrocarbylsulfonylalkyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol derivatives; treating atherosclerosis, dyslipidemia, diabetes, Alzheimers disease, and Niemann-Pick disease. |
| 03/11/2004 | US20040048912 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 03/11/2004 | US20040048911 Angiotensin II antagonists for treating cardiovascular disorders, hypertension, congestive heart failure and glaucoma. |
| 03/11/2004 | US20040048909 N-alkyl-N-(p-substituted-phenyl)benzylamine that is N-substituted with carbocyclic aminocarbonylalkylene, aminocarbonyl, or aminocarbonylaminosulfonyl; ACAT inhibitors; treating e.g.,hypercholesterolemia and atherosclerosis |
| 03/11/2004 | US20040048907 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/11/2004 | US20040048906 Synergistic combinations of amlodipine and atorvastatin used to treat angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects with symptoms of cardiac risk |
| 03/11/2004 | US20040048903 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes |
| 03/11/2004 | US20040048902 Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
| 03/11/2004 | US20040048901 Increased water solubility and bioabsorption; treatment of CNS disorders such as depression and emesis |
| 03/11/2004 | US20040048897 Il-8 receptor antagonists |
| 03/11/2004 | US20040048888 1,6-naphthyridineurea derivatives; treating excessive or undesirable angiogenesis and/or Tie2 receptor activity |
| 03/11/2004 | US20040048885 Imidazo[1,2,-A]pyridine ether compounds as ion channel modulators |
| 03/11/2004 | US20040048882 4-phenyl-6-alpha-(imidazolyl-, 1,2,4-triazolyl- or pyridyl)-benzyl substituted |
| 03/11/2004 | US20040048881 Quinazoline derivatives with anti-tumour activity |
| 03/11/2004 | US20040048872 Sedatives, anticonvulsants, hypnotics and general anesthetics. |
| 03/11/2004 | US20040048867 Especially quinoline carbonyl pyrrolidines with binding selectivity to benzodiazepine site of GABAA receptor to treatanxiety, depression, a sleep disorder, or cognitive impairment. |
| 03/11/2004 | US20040048859 Substituted glutarimides and their use as inhibitors of IL-12 production |
| 03/11/2004 | US20040048858 Chalcone derivatives and their use to treat diseases |
| 03/11/2004 | US20040048857 Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. |
| 03/11/2004 | US20040048855 Inhibitors of interleukin 1-beta converting enzyme |
| 03/11/2004 | US20040048853 Compounds, compositions, and methods |
| 03/11/2004 | US20040048852 Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| 03/11/2004 | US20040048850 Activators of soluble guanylate cyclase. |
| 03/11/2004 | US20040048846 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| 03/11/2004 | US20040048843 And aza- and diaza-derivatives thereof; especially treating allergy or nasal congestion |
| 03/11/2004 | US20040048840 Modulation of matrix metalloproteinase (MMP) activity with aldosterone blocker(s) |
| 03/11/2004 | US20040048820 Prevention or therapy of cardiovascular complications |
| 03/11/2004 | US20040048816 Restenosis treatment |
| 03/11/2004 | US20040048807 Angiogenesis inhibitors |
| 03/11/2004 | US20040048801 Use of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory:pre-and post-natal administration |
| 03/11/2004 | US20040048795 Stimulating a vagus nerve pathway in the brain; inhibiting apoptosis of a cardiac myocyte |
| 03/11/2004 | US20040048774 Inhibitors of IMPDH enzyme |
| 03/11/2004 | US20040048372 Extracting and recovering embryonic-like stem cells, including pluripotent or multipotent stem cells, from an exsanguinated human placenta; use of the isolated and perfused placenta as a bioreactor in which to propagate endogenous/exogenous cells |
| 03/11/2004 | US20040048356 Increases amounts of propionic acid or acetic acid in colon which can be used for preparation of a drugs that reduce the risk factors involved in the metabolic syndrome; increases the level of HDL cholesterol in serum, and reduces LDL,insulin |
| 03/11/2004 | US20040048338 IL-17 receptor like molecules and uses thereof |
| 03/11/2004 | US20040048325 Glycosyltransferase inhibitors |
| 03/11/2004 | US20040048316 Comprises phosphorescence and fluorescence resonance energy transfer; binding chenodeoxycholic acid to farnesoid X receptors; for regulating cholesterol absorption; for treatment of obesity |
| 03/11/2004 | US20040048294 Diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins |
| 03/11/2004 | US20040048286 Can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure |
| 03/11/2004 | US20040048280 A polynucleotide that includes an endothelial specific enhancer element |
| 03/11/2004 | US20040048266 Regulation of human membrane-type serine protease |
| 03/11/2004 | US20040048263 Novel g protein-coupled receptor protein and dna thereof |
| 03/11/2004 | US20040048245 Isolated polypeptide of given sequence; identifying modulators by contacting with compound and detecting binding activity; use in diagnosis and treatment |
| 03/11/2004 | US20040047922 Prevents the development of atherosclerosis |
| 03/11/2004 | US20040047896 Composition for improving age-related physiological deficits and increasing longevity |
| 03/11/2004 | US20040047895 Laver protein-containing composition and foods |
| 03/11/2004 | US20040047894 Preparation for improved dietary utilisation |
| 03/11/2004 | US20040047870 For therapy of atherosclerosis, cardiovascular disease, cerebrovascular disease, peripheral vascular disease, stenosis, restenosis and/or in-stent-stenosis |
| 03/11/2004 | US20040047860 Antibodies to human mcp-1 |
| 03/11/2004 | US20040047851 Treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase activity which comprises administering to the subject an amount of a zinc sphingomyelinase inhibitors effective to decrease |
| 03/11/2004 | US20040047842 Monascus purpureus mutants and their use in preparing fermentation products having blood pressure lowering activity |
| 03/11/2004 | DE10240343A1 Peroxynitrit-Umlagerungskatalysatoren Peroxynitrite rearrangement catalysts |
| 03/11/2004 | CA2496789A1 Methods for preserving organs and tissues |
| 03/11/2004 | CA2495914A1 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 03/11/2004 | CA2494754A1 Di and trifluoro-triazolo-pyridines anti-inflammatory compounds |
| 03/11/2004 | CA2493199A1 Peroxynitrite rearrangement catalysts used for the treatment or prophylaxis of diseases caused by peroxynitrite-mediated reactions |
| 03/11/2004 | CA2488739A1 Nitrogen-containing aromatic derivatives |
| 03/10/2004 | EP1396542A2 Novel P-selectin ligand protein |
| 03/10/2004 | EP1396494A1 Magnesium (-)hydroxycitrate and its applications |
| 03/10/2004 | EP1396492A1 Prodrug of an ice inhibitor |
| 03/10/2004 | EP1396488A1 Fused heterocyclic compound and medicinal use thereof |
| 03/10/2004 | EP1396487A1 Phenylpyridine carbonyl piperazine derivative |
| 03/10/2004 | EP1396271A1 Use of germination-activated ganoderma lucidium spores as anti-aging agent and against menopause symptoms |
| 03/10/2004 | EP1396266A1 Aqueous cilostazol preparation for injection |
| 03/10/2004 | EP1395684A2 New polynucleotides and polypeptides of the ifnalpha-7 gene |
| 03/10/2004 | EP1395652A2 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same |
| 03/10/2004 | EP1395609A2 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions |